| TRUE (N=89) |
|
|---|---|
| Age (years) | |
| Mean (SD) | 51.8 (10.2) |
| Median [Min, Max] | 54.0 [27.0, 74.0] |
| Treatment | |
| CCRT | 66 (74.2%) |
| Surgery | 23 (25.8%) |
| Stage | |
| II | 30 (33.7%) |
| III | 52 (58.4%) |
| IV | 7 (7.9%) |
| Metastasis | |
| Distant metastasis | 4 (4.5%) |
| Locoregional disease | 31 (34.8%) |
| Pelvic + Para-aortic LN metastasis | 11 (12.4%) |
| Pelvic LN metastasis | 43 (48.3%) |
| Histology | |
| Adenocarcinoma | 1 (1.1%) |
| Carcinoma in situ | 1 (1.1%) |
| Poorly differentiated carcinoma | 2 (2.2%) |
| Squamous cell carcinoma | 85 (95.5%) |
| DFS_status | |
| 0 | 70 (78.7%) |
| 1 | 19 (21.3%) |
| OS_status | |
| 0 | 87 (97.8%) |
| 1 | 2 (2.2%) |
| DFS_months | |
| Mean (SD) | 17.8 (12.7) |
| Median [Min, Max] | 13.5 [0.433, 43.4] |
| OS_months | |
| Mean (SD) | 20.7 (13.1) |
| Median [Min, Max] | 19.3 [0.433, 43.4] |